

Saatja: Chevalier, Aleksandra <Aleksandra.Chevalier@fortrea.com>
Saadetud: 03.04.2024 17:55
Adressaat: TA Info <info@terviseamet.ee>
Teema: ASR report for pre-market medical device study in Estonia query
Tähtsus: Kõrgeim

Dear Sir/Madam,

Hope this email finds you well.

We would like to confirm two topics related to pre-market device studies in Estonia.

1. Could you please provide reference from MDR on the content of ASR report for pre-market device study in Estonia?
2. Our Sponsor have decided to have 1 ASR per product per protocol per country. Could you please verify/confirm there is no regulation in Estonia or Europe (MDR 745-20017 requirement) against this decision?

Thank you

Best Regards,

Aleksandra Chevalier, MPharm
Drug Safety Associate, Drug Safety

E: fortrea.comFortrea Development Ltd

FortreaThis e-mail may contain confidential, proprietary, or protected information - including protected health information - that is meant to be viewed only by the intended recipient or company. Any unauthorized review, use, copying, downloading or disclosure is strictly prohibited. If this e-mail is not intended for you, or if you have received this e-mail in error, please notify the sender immediately. Do not forward it to any further recipients and permanently delete this e-mail and all attachments. If you have questions or concerns, please see our privacy policy on Fortrea.com